Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Keywords

MedicineImmunotherapyOncologyBiomarkerInternal medicinePrecision oncologyCancerGenetics

Affiliated Institutions

Related Publications

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang , Shengqing Gu , Deng Pan +12 more

2018 Nature Medicine 5230 citations

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Rina Hui , Leena Gandhi , Enric Carcereny +17 more

9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...

2016 Journal of Clinical Oncology 58 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Prospective identification of tumorigenic breast cancer cells

Muhammad Al‐Hajj , Max S. Wicha , Adalberto Benito‐Hernández +2 more

Breast cancer is the most common malignancy in United States women, accounting for >40,000 deaths each year. These breast tumors are comprised of phenotypically diverse popul...

2003 Proceedings of the National Academy o... 10263 citations

Publication Info

Year: 2018
Type: review
Volume: 30
Issue: 1
Pages: 44-56
Citations: 2769
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2769

OpenAlex

Cite This

APA Style

                            
                                
                                    Timothy A. Chan, 
                                
                                    Mark Yarchoan, 
                                
                                    Elizabeth M. Jaffee
                                
                                et al.
                            
                            (2018). 
                            Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. 
                            Annals of Oncology
                            , 30
                            (1)
                            , 44-56.
                            https://doi.org/10.1093/annonc/mdy495
                        

Identifiers

DOI: 10.1093/annonc/mdy495